Strange: Bullish FATE Analysts Actually See -9.12% Downside
October 29, 2020 at 08:43 AM EDT
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Fate Therapeutics Inc (FATE). The average 12-month price target for FATE — averaging the work of 13 analysts — reveals an average price target of $40.92/share..